ALLO vs. PROK, HUMA, TSHA, ALEC, FATE, CABA, CCCC, EDIT, VYGR, and VALN
Should you be buying Allogene Therapeutics stock or one of its competitors? The main competitors of Allogene Therapeutics include ProKidney (PROK), Humacyte (HUMA), Taysha Gene Therapies (TSHA), Alector (ALEC), Fate Therapeutics (FATE), Cabaletta Bio (CABA), C4 Therapeutics (CCCC), Editas Medicine (EDIT), Voyager Therapeutics (VYGR), and Valneva (VALN). These companies are all part of the "biological products, except diagnostic" industry.
Allogene Therapeutics (NASDAQ:ALLO) and ProKidney (NASDAQ:PROK) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, community ranking, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.
83.6% of Allogene Therapeutics shares are held by institutional investors. Comparatively, 51.6% of ProKidney shares are held by institutional investors. 24.3% of Allogene Therapeutics shares are held by company insiders. Comparatively, 45.0% of ProKidney shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
ProKidney has a net margin of 0.00% compared to Allogene Therapeutics' net margin of -202,366.25%. ProKidney's return on equity of 0.00% beat Allogene Therapeutics' return on equity.
Allogene Therapeutics received 261 more outperform votes than ProKidney when rated by MarketBeat users. However, 66.67% of users gave ProKidney an outperform vote while only 64.65% of users gave Allogene Therapeutics an outperform vote.
Allogene Therapeutics has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500. Comparatively, ProKidney has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500.
Allogene Therapeutics presently has a consensus price target of $13.50, indicating a potential upside of 389.13%. ProKidney has a consensus price target of $9.50, indicating a potential upside of 238.08%. Given Allogene Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Allogene Therapeutics is more favorable than ProKidney.
ProKidney has lower revenue, but higher earnings than Allogene Therapeutics. ProKidney is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Allogene Therapeutics had 1 more articles in the media than ProKidney. MarketBeat recorded 8 mentions for Allogene Therapeutics and 7 mentions for ProKidney. ProKidney's average media sentiment score of 0.95 beat Allogene Therapeutics' score of 0.48 indicating that ProKidney is being referred to more favorably in the news media.
Summary
Allogene Therapeutics beats ProKidney on 9 of the 17 factors compared between the two stocks.
Get Allogene Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALLO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALLO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Allogene Therapeutics Competitors List
Related Companies and Tools
